The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

AtaiBeckley has put up very strong share returns over the past few years, and that kind of run naturally raises the question ...

Wood said the transaction validates Christian Angermayer’s long-term psychedelic medicine vision. Lilly will pay $6.75 per share, including $2.8 billion upfront and up to $1 billion in milestones. The ...

Shares in key competitors COMPASS Pathways and MindMed have shown signs of recovery but Atai shares have remained unchanged. Major news items, such as FDA approval for MDMA-Assisted therapy and phase ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Atai's lead candidate, BPL-003, is an intranasal formulation that's being tested in a phase 3 trial for adults with treatment-resistant depression, which is defined as inadequate response to at least ...

Atai Life Sciences, a clinical-stage biopharmaceutical company focused on mental health treatments, announced the completion of a public offering on February 14, 2025, raising approximately $63.25 ...

Atai Life Sciences N.V. has surged >275% YTD, driven by promising psychedelic drug candidates targeting treatment-resistant depression and other mental health disorders. ATAI's lead asset, BPL-003, ...

Atai Life Sciences announced positive results from a Phase 2a study of BPL-003, a synthetic intranasal treatment for alcohol use disorder (AUD), showing that a single dose combined with relapse ...

Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression ...